Answer
Sorafenib tosilate may increase bleeding risk, and permanent discontinuation should be considered if a bleeding event requires medical intervention.
Sources for this answer
- Nexavar 200mg film-coated tabletsBayer plc · emc · SmPC §4.4 Special warnings and precautions for use · Version 32Document updated
Sources checked